Clinical experience with recombinant molecules for allergy vaccination

Current Topics in Microbiology and Immunology

Volumn 352, Issue 1, 2011, Pages 27-42

  Cromwell, Oliver ^a   Niederberger, Verena ^b   Horak, Friedrich ^b   Fiebig, Helmut ^a  

^a ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BINDING PROTEIN; BIRCH POLLEN ALLERGEN; BIRCH POLLEN EXTRACT; GAMMA INTERFERON; GRASS POLLEN ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MODULAR ANTIGEN TRANSLOCATION FEL D 1; NATURAL ALLERGEN; PLACEBO; POLLEN ANTIGEN; RAGWEED AMB A 1; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1; RECOMBINANT BET V 1 FRAGMENT; RECOMBINANT BET V 1 FV; RECOMBINANT BET V 1 TRIMER; RECOMBINANT CAT ALLERGEN FEL D 1; TOLL LIKE RECEPTOR 9; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALUMINUM HYDROXIDE; BET V 1; BET V 1A FRAGMENT; BET V 1A TRIMER; FEL D 1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 12; PHL P 1; PHL P 2; PHL P 5A; PHL P 5B; PHL P 6;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BIRCH; CLINICAL EFFECTIVENESS; CYTOKINE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; FOOD ALLERGY; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; IMMUNOTHERAPY; INJECTION SITE REACTION; NONHUMAN; OLIGOMERIZATION; OPTIMAL DRUG DOSE; ORAL ALLERGY SYNDROME; PHLEUM PRATENSE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECOMBINANT DNA TECHNOLOGY; REGULATORY T LYMPHOCYTE; RHINITIS; RHINOCONJUNCTIVITIS; SENSITIZATION; TH1 CELL; TH2 CELL; VACCINATION; ANTIGEN ANTIBODY REACTION; BASOPHIL; CIRCULAR DICHROISM; CLINICAL ASSESSMENT; CROSS REACTION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MAST CELL; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SKIN SENSITIVITY; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; SYMPTOM; T LYMPHOCYTE; TREATMENT DURATION;

ALLERGENS; ANIMALS; ANTIGENS, PLANT; CATS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; POLLEN; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 80053514862     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_129     Document Type: Article

References (49)

1. Akdis CA, Blaser K (2001) Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 22:175-178 (Pubitemid 32673650)
2. Akdis CA, Blesken T, Akdis M et al (1998) Role of interleukin 10 in specific immunotherapy. J Clin Invest 102:98-106 (Pubitemid 28323835)
3. Akdis M, Verhagen J, Taylor A et al (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199:1567-1575 (Pubitemid 38780411)
4. Allergome (2009) A platform for allergen knowledge, http://www.allergome. org
5. Andersson K, Lidholm J (2003) Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 130:87-107 (Pubitemid 36351233)
6. Breiteneder H, Hassfeld W, Pettenburger K et al (1988) Isolation and characterization of messenger RNA from male inflorescences and pollen of the white birch (Betula verrucosa). Int Arch Allergy Appl Immunol 87:19-24
7. Breiteneder H, Pettenburger K, Bito A et al (1989) The gene coding for the major birch allergen, Bet vI, is highly homologous to a pea disease resistance response gene. EMBO J 8:1935-1938 (Pubitemid 19273517)
8. Carballido JM, Carballido-Perrig N, Terres G et al (1992) Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: cytokine patterns change in response to the antigen concentration. Eur J Immunol 22:1357-1363
9. Crameri R, Fluckiger S, Daigle I et al (2007) Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 62:197-206 (Pubitemid 46090303)
10. Creticos PS, Schroeder JT, Hamilton RG et al (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. New Engl J Med 355:1445-1455 (Pubitemid 44511559)
11. Dahl R, Kapp A, Colombo G et al (2008) Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121:512-518
12. Didier A, Malling HJ, Worm M et al (2007) Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120:1338-1345 (Pubitemid 350225683)
13. Ferreira F, Briza P, Infuhr D et al (2006) Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5:5-14 (Pubitemid 43796677)
14. Frew AJ, Powell RJ, Corrigan CJ, Durham SR (2006) Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinocon-junctivitis. J Allergy Clin Immunol 117:319-325 (Pubitemid 43190146)
15. Gafvelin G, Thunberg S, Kronqvist M et al (2005) Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138:59-66 (Pubitemid 41291566)
16. Grönlund H, Bergman T, Sandström K et al (2003) Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 278:40144-40151 (Pubitemid 37248582)
17. Johansen N, Weber RW, Ipsen H et al (2009) Extensive IgE cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects. Int Arch Allergy Immunol 150:325-334
18. Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83
19. Jutel M, Akdis M, Budak F et al (2003) IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33:1205-1214 (Pubitemid 36609138)
20. Jutel M, Jaeger L, Suck R et al (2005) Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116:608-613 (Pubitemid 41267135)
21. Kahlert H, Weber B, Cromwell O, Fiebig H (2003) Evaluation of the allergenicity of hypoallergenic recombinant derivatives of Bet v 1 using basophil activation vy CD203c expression measurement. In: Marone G (ed) Clinical immunology and allergy in medicine. JGC Editions, Naples, pp 735-740
22. Kahlert H, Suck R, Weber B et al (2008) Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 145:193-206 (Pubitemid 351301311)
23. Kettner J, Meyer H, Cromwell O et al (2007a) Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV results of 2 years of treatment (Phase II trial). Allergy 62(Suppl. 83): 262 (Abstract)
24. Kettner J, Meyer H, Narkus A et al (2007b) Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious-results of a phase III study. Allergy 62(Suppl 83):33 (Abstract)
25. Klimek L, Bachert C, Doemer C et al (2005) Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV is clinically efficacious. Allergy Clin Immunol Int. Suppl 1:15 (Abstract)
26. Larche M, Akdis CA, Valenta R (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6:761-771 (Pubitemid 44453462)
27. Maasch HJ, Marsh DG (1987) Standardized extracts: Modified allergens-Allergoids. Clin Rev Allergy 5:89-106
28. Martinez-Gomez JM, Johansen P, Rose H et al (2009) Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 64:172-178
29. Moverare R, Elfman L, Vesterinen E et al (2002) Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57:423-430 (Pubitemid 34442156)
30. Narkus A, Kniest F, Menzel A et al. (2009) Clinical trials with recombinant allergens-three perspectives: industry. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe. Frankfurt AM 96:270-278
31. Niederberger V, Valenta R (2006) Molecular approaches for new vaccines against allergy. Expert Rev Vaccines 5:103-110
32. Niederberger V, Horak F, Vrtala S et al (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Nat Acad Sci USA 101:14677-14682 (Pubitemid 39346742)
33. Niederberger V, Reisinger J, Valent P et al (2007) Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 119:1013-1019
34. Pauli G, Purohit A, Oster JP et al (2000) Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 30:1076-1084 (Pubitemid 30619760)
35. Pauli G, Larsen TH, Rak S et al (2008) Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122:951-960
36. Purohit A, Niederberger V, Kronqvist M et al (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38: 1514-1525
37. Rappuoli R, Douce G, Dougan G, Pizza M (1995) Genetic detoxification of bacterial toxins: a new approach to vaccine development. Int Arch Allergy Immunol 108:327-333
38. Reisinger J, Horak F, Pauli G et al (2005) Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 116:347-354 (Pubitemid 41096542)
39. Ruedl C, Bachmann MF, Kopf M (2000) The antigen dose determines T helper cell subset development by regulation of CD40 ligand. Eur J Immunol 30:2056-2064 (Pubitemid 30456202)
40. Senti G, Kuster D, Martinez-Gomez JM et al (2009) Intralymphatic allergen specific immunotherapy using modified recombinant allergen targeting the MHC class II pathway: a double-blind placebo-controlled clinical trial in cat dander allergic patients. Allergy 64(Suppl 90):74 (Abstract)
41. Sprung V, Pfaar O, Klimek L et al (2009) Safety and efficacy of recombinant grass pollen allergens: a dose-response study. Allergy 64(Suppl 90):147 [Abstract]
42. Tighe H, Takabayashi K, Schwartz D et al (2000) Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106:124-134 (Pubitemid 30482862)
43. Tryba M (1994) Akuttherapie anaphylaktoider Reaktionen. Ergebnis einer interdisziplinären Konsensuskonferenz. Allergo J 3:211-224 (Pubitemid 24208438)
44. Van Der Heijden FL, van Neerven RJJ, van Katwijk M et al (1993) Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 150:3643-3650 (Pubitemid 23129745)
45. Van Hage-Hamsten M, Kronqvist M, Zetterström O et al (1999) Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104:969-977 (Pubitemid 29532117)
46. Vrtala S, Hirtenlehner K, Vangelista L et al (1997) Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments-candidates for a novel form of specific immunotherapy. J Clin Invest 99:1673-1681 (Pubitemid 27163818)
47. Vrtala S, Akdis CA, Budak F et al (2001a) T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 165:6653-6659
48. Vrtala S, Hirtenlehner K, Susani M et al (2001b) Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J 15:2045-2047
49. Weber B, Slamal H, Suck R (2003) Size exclusion chromatography as a tool for quality control of recombinant allergens and hypoallergenic variants. J Biochem Biophys Meth 56:219-232 (Pubitemid 36776603)